Evidence map›Paper›PMID 32712333›Full record

SynthesisInternational journal of antimicrobial agents2020

Tocilizumab for severe COVID-19: a systematic review and meta-analysis.

Shao-Huan Lan, Chih-Cheng Lai, Hui-Ting Huang, Shen-Peng Chang, Li-Chin Lu, Po-Ren Hsueh

Abstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in International journal of antimicrobial agents, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 108 papers, 17 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
108citing papers in PubMed, 17 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

108 citing papers in PubMed, 17 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Pooled it
  15. Pooled it
  16. Pooled it
  17. Pooled it
  18. Trial
  19. Trial
  20. Trial

48 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Shao-Huan LanSchool of Pharmaceutical Sciences and Medical Technology, Putian University, Putian 351100, China.
Chih-Cheng LaiDepartment of Internal Medicine, Kaohsiung Veterans General Hospital, Tainan Branch, Tainan, Taiwan.
Hui-Ting HuangDepartment of Pharmacy, Chi Mei Medical Center, Liouying, Taiwan.
Shen-Peng ChangYijia Pharmacy, Tainan 70846, Taiwan.
Li-Chin LuSchool of Management, Putian University, Putian 351100, China.
Po-Ren HsuehDepartment of Laboratory Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan; Department of Internal Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan. Electronic address: hsporen@ntu.edu.tw.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This systemic review and meta-analysis aimed to assess the efficacy of tocilizumab for the treatment of severe coronavirus disease 2019 (COVID-19). Candidate studies up to 24 May 2020 were identified from PubMed, Cochrane Library, Embase, medRxiv and bioRxiv. Treatment outcomes included mortality, risk of intensive care unit (ICU) admission and the requirement for mechanical ventilation (MV). Seven retrospective studies involving 592 adult patients with severe COVID-19, including 240 in the tocilizumab group and 352 in the control group, were enrolled. All-cause mortality of severe COVID-19 patients among the tocilizumab group was 16.3% (39/240), which was lower than that in the control group (24.1%; 85/352). However, the difference did not reach statistical significance [risk ratio (RR) = 0.62, 95% confidence interval (CI) 0.31-1.22; I

Indexed as

Antibodies, Monoclonal, HumanizedAnti-Inflammatory AgentsAntiviral AgentsBacterial InfectionsBetacoronavirusCoronavirus InfectionsCOVID-19Cytokine Release SyndromeCytokinesDrug Administration ScheduleHumansImmunologic FactorsIntensive Care UnitsOpportunistic InfectionsPandemicsPneumonia, ViralAntibodies, Monoclonal, HumanizedAnti-Inflammatory AgentsAntiviral AgentsCytokinesImmunologic FactorstocilizumabCOVID-19Intensive care unitMechanical ventilationMortalitySARS-CoV-2Tocilizumab

Identifiers

PMID32712333
PMCPMC7377685

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.